ClinicalTrials.gg
RecruitingNCT06942221DIGNITY - HFUpdated Dec 2, 2025

Digital Solutions in Heart Therapy (DIGNITY)

An interventional study of usual care and guideline-directed medical therapy in Heart Failure With Reduced Ejection Fraction, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Heart Failure by University Hospital, Basel, Switzerland — 2 open to participants now, 3 under way, none of them phase 3. Heart Failure · University Hospital, Basel, Switzerland.

Started
2025
with 1 other
No phase
5 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Heart Failure by University Hospital, Basel, Switzerland, this one is one of 2 that started in 2025, is one of 5 with no phase, and was the 10th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

2 of the 11 studies in Heart Failure by University Hospital, Basel, Switzerland are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Heart Failure by University Hospital, Basel, Switzerland, or all of them as a file.
02

Study summary

This study aims to assess the safety and effectiveness of telemedicine guided strategy on guideline-directed medical therapy (GDMT) optimization in hospitalized patients with heart failure in comparison to usual care in Switzerland.

Read the detailed description

Heart failure (HF) is a chronic condition affecting approximately 26 million people worldwide, with acute decompensations leading to frequent hospitalizations and increased mortality. While guideline-directed medical therapy (GDMT) has been shown to improve outcomes in HF with reduced ejection fraction (HFrEF), real-world data indicate suboptimal implementation, with delayed initiation and low adherence to target doses. The STRONG-HF study demonstrated that rapid up-titration of GDMT following hospitalization significantly reduces HF-related mortality and readmission, highlighting the importance of early and structured treatment optimization. However, close monitoring during the vulnerable post-discharge phase remains resource-intensive and difficult to implement in routine care.

The DIGNITY study aims to assess the safety and effectiveness of a telemedicine-guided strategy for optimizing GDMT in patients with HFrEF compared to usual care in Switzerland after discharge. The study hypothesizes that telemedicine-supported management will improve GDMT optimization and clinical outcomes in this high-risk patient population.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction

Browse trials for

Keywords

  • guideline-directed medical therapy
  • telemedicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 18 years at the time of hospital admission
  2. Ability to use a (smart)phone and/or tablet for the follow-up
  3. Documented (LVEF) > 40% assessed within preceding 12 months
  4. Not treated with optimal doses of oral HF therapies within 2 days before anticipated hospital discharge for acute HF in at least one of the medication categories (for details see Table 1 on page 10)
  5. Hospitalized due to acute HF decompensation.
  6. Specific measures within 24 hours prior to randomization

    • Systolic blood pressure > 100 mmHg, and heart rate > 60bpm
    • Serum potassium \< 5mmol/L

Exclusion criteria

Exclusion Criteria:

  1. Inability to use a (smart)phone or tablet
  2. Clear intolerance to high doses of betablockers, ACE inhibitors, or ARBs
  3. Estimated \<30ml/min/1.73m2 or dialysis
  4. Myocardial infarction, unstable angina or cardiac surgery within 3 months, percutaneous transluminal coronary intervention within 1 months prior to screening
  5. Cardiac resynchronization therapy device implantation within 3 months prior to screening
  6. Presence of significant obstructive lesion of the left ventricular outflow tract
  7. Amyloid cardiomyopathy
  8. Participation in other clinical trials for drugs
  9. Pregnant or nursing women
  10. Women of who are unwilling to abstain from sexual intercourse with men or practice appropriate
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    telemedicine guided care group

    Patients will be instructed to response to questions using the App daily. The parameters and questionnaires will be evaluated by the Telemedicine team, and participants will be contacted via phone 1 week after discharge and subsequently every 7-10 days to discuss the up-titration of the HF medications.

    Other: guideline-directed medical therapy

  • Active comparator
    usual care group

    usual care according to local practice

    Other: usual care

Interventions

  • Otherusual care

    Patients in the "usual care group" will be followed up according to the local practice until the end of the study.

  • Otherguideline-directed medical therapy

    Patients are followed via an App, data will be evaluated by the Telemedicine team, and participants will be contacted via phone 1 week after discharge and subsequently every 7-10 days to discuss the up-titration of the HF medications.

    Also known as: telemedicine

06

What researchers measure

Primary outcomes

  1. composite guideline-directed medical therapy optimization score

    composite guideline-directed medical therapy (GDMT) score is defined as the sum of care optimization changes and care deoptimization changes at 3 months post discharge.

    Time frame: 3 month post-discharge

Secondary outcomes

  1. Proportion of clinical encounters setting 1

    Proportion of clinical encounters with GDMT initiations when these therapies were not used at discharge

    Time frame: during whole study phase from randomization to 90 days post-discharge

  2. Proportion of clinical encounters setting 2

    Proportion of clinical encounters with either GDMT initiations and/ or dose uptitrations, net GDMT intensification and changes in the prescription of individual GDMT elements from time to hospital admission to discharge

    Time frame: during whole study phase from randomization to 90 days post-discharge

  3. Dosage of diuretics

    Requirement for decreasing or increasing dose of diuretics

    Time frame: during whole study phase from randomization to 90 days post-discharge

  4. Proportion of safety issues

    Safety outcomes including incidence of hypotension, hyperkalemia, acute kidney failure (doubling of baseline serum creatinine)

    Time frame: during whole study phase from randomization to 90 days post-discharge

  5. Proportion of heart failure

    Re-hospitalization due to heart failure decompensation

    Time frame: during whole study phase from randomization to 90 days post-discharge

  6. Proportion of hospitalization

    All-cause re-hospitalization

    Time frame: during whole study phase from randomization to 90 days post-discharge

  7. Quality of life score

    Quality of life (Kansas City Cardiomyopathy Questionnaire (KCCQ).

    Time frame: at randomization and 90 days post-discharge

  8. Optimization score

    Optimization score is defined as the sum of care optimization changes and care deoptimization changes.

    Time frame: at randomization and 90 days post-discharge

  9. Patient Health Questionnaire

    The Patient Health Questionnaire (PHQ-2) measures the frequency of depressed mood, with a score ranging from 0 to 6.

    Time frame: at randomization and 90 days post-discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 17 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2025
First posted
Apr 24, 2025
StartActual
Jul 17, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06942221
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Jul 17, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 2, 2025

Study contacts

Qian Zhou, Prof. MD
Contact
qian.zhou@usb.ch
+41 3286828
Qian Zhou, Prof. MD
principal investigator · Universitätsspital Basel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion